Papers: 10.1007/s00262-020-02487-x

https://doi.org/10.1007/s00262-020-02487-x

Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB–IV M1c melanoma patients

Cited by: 18
Author(s): A. Fröhlich, Dennis Niebel, Simon Fietz, E Egger, A. Buchner, Judith Sirokay, Jennifer Landsberg
Published: over 6 years ago

Software Mentions 1